You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Medtronic
McKinsey
Dow
Harvard Business School

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Anlotinib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Anlotinib?

Anlotinib is an investigational drug.

There have been 151 clinical trials for Anlotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 26th 2019.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, and Sun Yat-sen University.

There are seven US patents protecting this investigational drug and fifty-eight international patents.

Recent Clinical Trials for Anlotinib
TitleSponsorPhase
TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal CancerDong WangN/A
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 TrialSun Yat-sen UniversityPhase 3
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal CancerShanghai Zhongshan HospitalPhase 2

See all Anlotinib clinical trials

Clinical Trial Summary for Anlotinib

Top disease conditions for Anlotinib
Top clinical trial sponsors for Anlotinib

See all Anlotinib clinical trials

US Patents for Anlotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Anlotinib   Start Trial Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts Advenchen Pharmaceuticals, LLC (Moorpark, CA)   Start Trial
Anlotinib   Start Trial Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same   Start Trial
Anlotinib   Start Trial Method for treating tumour, pharmaceutical composition and medicinal kit   Start Trial
Anlotinib   Start Trial Quinoline derivative against non-small cell lung cancer   Start Trial
Anlotinib   Start Trial Spiro substituted compounds as angiogenesis inhibitors   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Anlotinib

Drugname Country Document Number Estimated Expiration Related US Patent
Anlotinib Australia 2016257816 2035-05-04   Start Trial
Anlotinib Brazil 112017023639 2035-05-04   Start Trial
Anlotinib Canada 2984444 2035-05-04   Start Trial
Anlotinib China 107771078 2035-05-04   Start Trial
Anlotinib China 110172057 2035-05-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Medtronic
McKinsey
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.